Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287535 | 1.00 | CYP2D6 (0.45) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| SCHEMBL1711365 | 1.00 | CYP2D6 (0.45) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| Water SCHEMBL11017550 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| SCHEMBL10886657 | 0.93 | CYP2D6 (0.41) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| SCHEMBL7198639 | 0.82 | KDM4E (0.52) | CYP2D6CYP3A4NFKB1LMNAALDH1A1 | |
| SCHEMBL27218519 | 0.81 | DPP4 (0.33) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| SCHEMBL11295470 | 0.81 | DPP4 (0.33) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| SCHEMBL30678523 | 0.81 | CYP2D6 (0.54) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| SCHEMBL14395925 | 0.81 | CYP2D6 (0.54) | CYP2D6CYP1A2CYP3A4NFKB1PNMT | |
| SCHEMBL30678522 | 0.81 | CYP2D6 (0.54) | CYP2D6CYP1A2CYP3A4NFKB1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113061313-A | Flexible perovskite scintillator thick film and preparation method thereof | 华中科技大学 | 2021-07-02 | — | — | CN | claimed |
| EP-0108813-A1 | GRAFTED CHROMATOGRAPHIC FILLER AND METHOD FOR ANALYZING ENANTIOMER MIXTURE USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-23 | — | — | EP | claimed |
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSTY | 2024-05-02 | — | — | US | disclosed |
| CN-109461820-B | Two-dimensional lead-free organic-inorganic hybrid perovskite diode photodetector and preparation method thereof | 天津理工大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-113061313-A | Flexible perovskite scintillator thick film and preparation method thereof | 华中科技大学 | 2021-07-02 | — | — | CN | disclosed |
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| WO-2017070482-A2 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20070134772-A1 | Thermostable Omega-Transaminases | CAMBREX KARISKOGA AB | 2007-06-14 | — | — | US | disclosed |
| EP-1295862-A1 | INTERMEDIATE AND PROCESS FOR PRODUCING FLUORINATED CARBOXYLIC ACID DERIVATIVE FROM THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6054594-A | Process for the production of enantiomerically enriched N-acylazetidine-2-carboxylic acids | ASTRA AB (SE) | 2000-04-25 | — | — | US | disclosed |
| CN-1012644-B | Process for preparing flavanone derivatives | MERCK PATENT GES MITBESCHRANKT (DE) | 1991-05-22 | — | — | CN | disclosed |
| WO-1989001342-A2 | DIAGNOSTIC OR RADIOTHERAPEUTIC COMPOSITION COMPRISING A HYDROGEN CONTAINING COMPOUND | MALLINCKRODT, INC. (US) | 1989-02-23 | — | — | WO | disclosed |
| EP-0246002-A2 | Alkenamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-11-19 | — | — | EP | disclosed |
| EP-0098892-B1 | PROCESS FOR PREPARING 1,5-BENZOTHIAZEPINE DERIVATIVES | Tanabe Seiyaku Co., Ltd. (JP) | 1987-10-28 | — | — | EP | disclosed |
| CN-85105079-A | The preparation of flavanone derivative | — | 1987-01-28 | — | — | CN | disclosed |
| EP-0072259-B1 | AMINONAPHTHACENE DERIVATIVES, THEIR PRODUCTION AND ANTI-TUMOR OR ANTI-MICROBIAL COMPOSITIONS CONTAINING THEM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA7, PSMA6, PSMA1 | CYP2D6 4415/4885CYP1A2 4363/4885CYP3A4 3690/4885 |
| US-20070134772-A1 | Thermostable Omega-Transaminases | FADS2, SCD, CES1 | CYP2D6 229/4885CYP1A2 277/4885CYP3A4 194/4885 |
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA3, PSMA6, PSMA7 | CYP2D6 4250/4885CYP1A2 3968/4885CYP3A4 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.